 This study is designed to determine the efficacy and safety of allogeneic bone marrow-derived mesenchymal stem cells in kidney transplantation from Chinese donation after citizens death DCD. A pair uremia patients receiving kidney grafts from a same donor are randomized into two groups: MSCs group and control group. Besides routine induction therapy ATG or Basiliximab and maintenance immunosuppressive drugs low-dose Tacrolimus MPA prednisone, patients in MSCs group are administered MSCs treatment 1106kg. Allogeneic bone marrow-derived MSCs 1106kg are given intravenously at day 0 post renal reperfusion during surgery, day 7, day 14 and day 21. The renal allograft function, rejection, patientgraft survival and severe adverse events within 12 months post-transplant are monitored. 